Medtronic: FDA Approves Revised Commercial Labeling For Intellis Platform

(RTTNews) - Medtronic plc (MDT) announced the FDA has approved revised commercial labeling for the Intellis Platform with Differential Target Multiplexed programming for the treatment of chronic, intractable back and leg pain. The company noted that the new labeling will include study outcomes from a multicenter randomized control trial reflecting superior back pain relief with Differential Target Multiplexed Spinal Cord Stimulation when compared to conventional Spinal Cord Stimulation.

Charlie Covert, vice president and general manager, Pain Therapies within the Neuromodulation business, which is part of the Neuroscience Portfolio at Medtronic, said: "The updated labeling further strengthens the credibility of the outcomes from this therapy, and parallels the profound benefits our clinician partners are seeing with their own patients."